

January 19, 2021

Comments on OPP “Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review” (Nov 3, 2020)

Submitted online via *Regulations.gov* to docket EPA-HQ-OPP-2013-0244-0022

These comments are submitted on behalf of the undersigned scientists. We declare collectively that we have no direct or indirect financial or fiduciary interest in any chemical or product that is the subject of these comments. The co-signers’ institutional affiliations are included for identification purposes only and do not imply institutional endorsement or support unless indicated otherwise.

We appreciate the opportunity to provide written comments on the US EPA’s Office of Chemical Safety and Pollution Prevention “Draft Human Health and Ecological Risk Assessment in Support of Registration Review.”¹ Ethylene oxide is classified as “carcinogenic to humans” by the International Agency for Research on Cancer ² and the US Environmental Protection Agency (EPA),³ and is “known to be a human carcinogen” by the National Toxicology Program.⁴ Ethylene oxide has a mutagenic mode of action (MOA) and there is no ‘safe’ level of exposure to this chemical.⁵

The Office of Pollution Prevention (OPP) draft presents multiple approaches for cancer risk estimation without critical analysis, treating them as if they are equally valid, which they are not. Moreover, OPP fails to use EPA’s own Office of Research and Development’s (ORD)/ Integrated Risk Information System (IRIS) assessment, which was the result of a comprehensive and rigorous development and review processes, in which OPP, itself, participated.⁶

In 2016, after public comments and extensive input from an independent Science Advisory Board (SAB) peer review panel, EPA’s IRIS program finalized a unit risk estimate of 5.0×10^{-3} (per ug/ m³) for ethylene oxide based on lymphoid and breast cancers and accounting for

¹ OPP (2020). Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review. (Memorandum) From: Leighton, T; Donovan, W. To: Bailey, J; Bartow, S. November 3, 2020.

² IARC. (2018) Ethylene Oxide. Available: <https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100F-28.pdf>

³ EPA. (2016) Evaluation of The Inhalation Carcinogenicity of Ethylene Oxide (Final Report). EPA/635/R-16/350F. Available: https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=329730

⁴ NTP/NIEHS. (2016) Report on Carcinogens, Fourteenth Edition: Ethylene Oxide. Available: <https://ntp.niehs.nih.gov/ntp/roc/content/profiles/ethyleneoxide.pdf>

⁵ National Research Council. (2009) Science and Decisions: Advancing Risk Assessment. Washington, DC: National Academies Press.

⁶ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris.

potential increased risks from early-life exposures.⁷ The EPA value was derived using established methodology and current principles for risk assessment as encompassed in EPA's Guidelines for Carcinogen Risk Assessment and other Agency guidance documents, and the modeling approaches used in the EPA's 2016 assessment were endorsed by the SAB panel.⁸ EPA's 2016 assessment was many years in the making, with multiple agency, interagency, public comment, and independent peer review steps, some of which are acknowledged in the OPP draft.⁹ As such, the 2016 EPA value reflects the best available science necessary to ensure the protection of the public's health from cancer risks.

In contrast, the 2020 Texas Commission on Environmental Quality (TCEQ) assessment was based on a contractor product with much more limited input and review.¹⁰ The model used in the TCEQ's 2020 assessment does not represent the lymphoid cancer data, and instead of reporting model fit statistics, the TCEQ assessment provides an erroneous "reality check" to attempt to support their model, as outlined by our previous comments to TCEQ in 2019 (Appendix A). Another serious defect is that the TCEQ assessment provides no risk estimates for breast cancer. As discussed below, the comments from the limited TCEQ peer review were generally split on the major issues of breast cancer and the modeling. Faced with divergent comments, TCEQ made decisions which are not protective of public health and chose to maintain the flawed assessment.

Our analysis found that the EtO Task Force (EOTF) assessment, as summarized in the OPP draft, suffers from the same problems as the TCEQ assessment.¹¹ In addition, the EOTF submission and supporting Exponent report are industry products with no public review, and they are not available to the public.

We note that the TCEQ and EOTF assessments do not reflect any new data or hypotheses that were not available to ORD/IRIS or the SAB at the time of its 2016 assessment, merely analyses and approaches that were rejected by ORD/IRIS and the SAB.

⁷ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris.

⁸ SAB (Science Advisory Board). (2015). Science Advisory Board Review of the EPAs evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board.
[https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/\\$File/EPA-SAB-15-012+unsigned.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/$File/EPA-SAB-15-012+unsigned.pdf)

⁹ OPP (2020). Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review. (Memorandum) From: Leighton, T; Donovan, W. To: Bailey, J; Bartow, S. November 3, 2020. Pg 24.

¹⁰ Texas Commission on Environmental Quality (TCEQ) (2020a). Ethylene Oxide, Carcinogenic Dose-Response Assessment. CAS Registry Number: 7521-8. Development Support Document, Final, May 15, 2020. Prepared by Joseph T. Haney, Sabine S. Lange, Allison Jenkins, Jessica L. Myers, Toxicology, Risk Assessment, and Research Division.

¹¹ OPP (2020). Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review. (Memorandum) From: Leighton, T; Donovan, W. To: Bailey, J; Bartow, S. November 3, 2020.

Our comments on the OPP draft risk evaluation address the following main issues:

- 1. The Texas Commission on Environmental Quality (TCEQ) and EtO Task Force (EOTF) assessments inappropriately discount the breast cancer risk and therefore drastically underestimate the potential risks of Ethylene Oxide to women.**
- 2. The TCEQ assessment uses a model for lymphoid cancer that does not reflect the data, uses a number of non-standard and non-health-protective procedures in the calculation of the risk estimate for lymphoid cancer from that model, and uses an erroneous “reality check” to support the use of that model. The EOTF assessment improperly chooses the same model and obtains the same risk estimate as TCEQ.**
- 3. The Office of Pollution Prevention should not consider the EOTF submission and supporting Exponent report, as they are industry products with no public review, and they are not available to the public.**
- 4. The TCEQ/EOTF unit risk estimate should not be considered a legitimate estimate and should not be included in any range of reasonable, scientifically supported estimates.**

We appreciate the opportunity to provide public input. Please do not hesitate to contact us with any questions regarding these comments.

Sincerely,

Jennifer Jinot
Scientific consultant to University of California, San Francisco
(Retired from U.S. Environmental Protection Agency)

Swati Rayasam, MSc Science Associate, Science & Policy
Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

Aditi Shah, MPH Science and Policy Analyst, Science & Policy
Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

Nicholas Chartres, PhD Associate Director, Science & Policy
Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

Tracey Woodruff, PhD, MPH
Professor and Director, Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

DETAILED COMMENTS

1. The Texas Commission on Environmental Quality (TCEQ) and EtO Task Force (EOTF) assessments inappropriately discount the breast cancer risk and therefore drastically underestimate the potential risks of Ethylene Oxide to women.

EPA's 2016 assessment found strong evidence of a breast cancer hazard in females from ethylene oxide exposure.¹² Not only did the SAB concur, it in fact recommended that EPA strengthen its discussion of the breast cancer evidence.¹³ EPA's finding is based on the total weight of the evidence regarding breast cancer. This includes evidence from human studies, rodent carcinogenicity studies, and mechanistic studies. As discussed in detail in section 3.1 and summarized in section 3.1.1, the human evidence includes "strong evidence of an elevated risk of breast cancer from exposure to EtO in a few studies. The clearest evidence comes from the large NIOSH studies [(Steenland et al., 2004; Steenland et al., 2003], which found positive exposure--response relationships for both breast cancer incidence and mortality (319 incident breast cancer cases; 103 breast cancer deaths). In addition, a recent follow-up study of a Swedish cohort of sterilizer workers reported significant increases in the incidence rate ratios in the highest two cumulative exposure quartiles compared to the workers with cumulative exposure-s below the median [Mikoczy et al., 2011]. Of the four other studies that included females, none approached the size of the NIOSH studies in terms of breast cancer data—the

¹² EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris.

¹³ SAB (Science Advisory Board). (2015). Science Advisory Board Review of the EPAs evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board. [https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/\\$File/EPA-SAB-15-012+unsigned.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/$File/EPA-SAB-15-012+unsigned.pdf)

study with the next largest breast cancer database had only 12 cases. Nonetheless, two of the four other studies were supportive of an increased risk of breast cancer.”^{14,15,16,17}

In section 3.2 of its 2016 assessment, EPA also concluded that there was sufficient evidence of ethylene oxide carcinogenicity in laboratory animals, based on findings of tumors at multiple sites in both sexes of both rats and mice, including mammary carcinoma in female mice, suggesting some site concordance with the breast cancers observed in humans.¹⁸ In addition, Section 3.4.1.3 of the assessment discusses some of the supporting mechanistic evidence specific to ethylene oxide and breast cancer development.¹⁹

TCEQ’s 2020 assessment, on the other hand, chose to ignore the breast cancer hazard.²⁰ The TCEQ conclusions are based largely on epidemiological analyses focusing on **external** comparisons, which are notoriously problematic because the general population is often a poor comparison group for a worker population for a number of reasons (e.g., health status) so internal comparisons are almost always preferred for occupational cohorts. In 2015, EPA’s SAB concurred with EPA’s preference for **internal** comparisons and recommended EPA “down-weight epidemiologic results based on external standards.”²¹ In focusing on external comparisons, the TCEQ report cites a single Norwegian study to argue against a “healthy worker effect” (HWE) for breast cancer in incidence studies. However, other studies, showing statistically significant decreased standardized incidence ratios, indicative of a HWE, are ignored.²² In addition, TCEQ’s assessment suggests that parity was not sufficiently controlled in the Steenland et al. (2003) study;²³ however, parity was considered and was included in the final

¹⁴ Steenland, K; Whelan, E; Deddens, J; Stayner, L; Ward, E. (2003). Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). *Cancer Causes Control* 14: 531-539. <http://dx.doi.org/10.1023/A:1024891529592>

¹⁵ Steenland, 2004. Mortality Analyses in a Cohort of 18,235 Ethylene Oxide Exposed Workers: Follow up Extended from 1987 to 1998, K. Steenland, L. Stayner and J. Deddens, *Occupational and Environmental Medicine*, Jan., 2004, Vol. 61, No. 1 (Jan.,2004), pp. 2-7

¹⁶ Mikoczy, Z; Tinnerberg, H; Björk, J; Albin, M. (2011). Cancer incidence and mortality in Swedish sterilant workers exposed to ethylene oxide: Updated cohort study findings 1972-2006. *Int J Environ Res Public Health* 8: 2009-2019. <http://dx.doi.org/10.3390/ijerph8062009>

¹⁷ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris. Pg. 3-13

¹⁸ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris.

¹⁹ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris.

²⁰ Texas Commission on Environmental Quality (TCEQ) (2020a). Ethylene Oxide, Carcinogenic Dose-Response Assessment. CAS Registry Number: 7521-8. Development Support Document, Final, May 15, 2020. Prepared by Joseph T. Haney, Sabine S. Lange, Allison Jenkins, Jessica L. Myers, Toxicology, Risk Assessment, and Research Division.

²¹ SAB (Science Advisory Board). (2015). Science Advisory Board Review of the EPAs evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board. [https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/\\$File/EPA-SAB-15-012+unsigned.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/$File/EPA-SAB-15-012+unsigned.pdf). Pg. 3

²² Sont, WN; Zielinski, JM; Ashmore, JP; et al. (2001) First Analysis of Cancer Incidence and Occupational Radiation Exposure Based on the National Dose Registry of Canada. *Am J Epidemiol* 159:309-18.

²³ Texas Commission on Environmental Quality (TCEQ) (2020a). Ethylene Oxide, Carcinogenic Dose-Response Assessment. CAS Registry Number: 7521-8. Development Support Document, Final, May 15, 2020. Prepared by Joseph T. Haney, Sabine S. Lange, Allison Jenkins, Jessica L. Myers, Toxicology, Risk Assessment, and Research Division, pg. 26.

model, and it is speculative to claim that this was inadequate.²⁴ Duration had a marginally stronger association than cumulative exposure, but it is a more general metric and this should not be overinterpreted. TCEQ also tries to downplay site concordance, citing a 2019 IARC report out of context.²⁵ Site concordance across species is not obligatory but can strengthen the overall evidence,²⁶ and that view is consistent with the IARC report.²⁷

Finally, overall, the TCEQ peer reviewer comments were not supportive of ignoring the potential breast cancer risk. An evaluation of the breast cancer evidence relies heavily on an assessment of epidemiological data. There were two epidemiologists in the group of six reviewers, and they appeared to be split over the conclusion.²⁸ One (#1) concluded that the breast cancer data “support a causal relation”;²⁹ the other (#3) agreed with TCEQ’s judgment not to include breast cancer in their quantitative assessment, but noted that it was a “judgment call” and that “arguments can be made for having made a different decision.”³⁰ This latter acknowledgement is consistent with a conclusion that TCEQ made a judgment not to protect women from the potential risk of breast cancer. Another reviewer (#5) was satisfied with TCEQ’s determination that regulatory decisions should be based solely on the lymphohematopoietic cancer risks but qualified this with the statement that “A major contributor to [the reviewer’s] attitude is the expectation that appropriate handling of lymphohematopoietic cancer should also lead to decisions that are protective against other cancer risks, including breast cancer.”³¹ In a similar vein, a fourth reviewer (#6) found the evidence for a breast cancer association not convincing, “but suggestive”³² and proposed that “an estimate of [the] potential carcinogenicity [of ethylene oxide for breast cancer] could be included in TCEQ’s analysis in the interest of not underestimating or appearing to underestimate the carcinogenicity of [ethylene oxide]”.³³ However, by discounting breast cancer, TCEQ drastically underestimated the potential risks to women.³⁴

²⁴ Steenland, K; Whelan, E; Deddens, J; Stayner, L; Ward, E. (2003). Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). *Cancer Causes Control* 14: 531-539. <http://dx.doi.org/10.1023/A:1024891529592>, pg. 534.

²⁵ Texas Commission on Environmental Quality (TCEQ) (2020a). Ethylene Oxide, Carcinogenic Dose-Response Assessment. CAS Registry Number: 7521-8. Development Support Document, Final, May 15, 2020. Prepared by Joseph T. Haney, Sabine S. Lange, Allison Jenkins, Jessica L. Myers, Toxicology, Risk Assessment, and Research Division, pg. 28.

²⁶ EPA (U.S. Environmental Protection Agency). (2005). Guidelines for carcinogen risk assessment [EPA Report] (pp. 1-166). (EPA/630/P-03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. <http://www2.epa.gov/osa/guidelines-carcinogen-risk-assessment>

²⁷ International Agency for Research on Cancer (IARC). (2019). Tumour site concordance and mechanisms in carcinogenesis. IARC Scientific Publication No. 165, Lyon, France: International Agency for Research on Cancer.

²⁸ Reviewers were identified by number, not name, in the comments; however, by inference, these appeared to be reviewers #1 and #3, as they focused on the epidemiological issues in their comments and sometimes deferred on the non-epidemiological issues on the grounds of those issues being outside of these reviewers’ expertise.

²⁹ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020, Pg. 23

³⁰ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020, Pg. 25

³¹ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020, Pg. 27

³² TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020, Pg. 27

³³ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020, Pg. 53

³⁴ EPA’s unit risk estimate for breast cancer incidence from ethylene oxide exposure is 1.5×10^{-3} per ppb (ADAF-unadjusted) based on the selected two-piece linear spline model (EPA, 2016); this is almost 3 orders of magnitude greater than TCEQ’s estimate of 2.5×10^{-6} per ppb

As summarized in the OPP draft, the EOTF submission similarly disregards breast cancer, and the stated reasons are laughable, overplaying a couple issues in the Steenland et al. studies and ignoring all the rest of the breast cancer evidence.^{35,36} Reportedly, the EOTF submission correctly notes that the Steenland et al. (2003) incidence study had incomplete ascertainment of incident breast cancer cases;³⁷ however, that is in part why the 2016 EPA assessment focused on the sub-cohort with interviews.³⁸ In addition, the EOTF submission was reportedly deterred because the evidence from Steenland et al. (2004) was “only suggestive for breast cancer mortality compared to lymphoid mortality,”³⁹ disregarding that Steenland et al. (2004)⁴⁰ found the evidence suggestive but merely weaker than the lymphoid mortality results and ignoring the Steenland et al. (2003)⁴¹ breast cancer incidence results and, again, all the rest of the breast cancer evidence.

2. The TCEQ assessment uses a model for lymphoid cancer that does not reflect the data, uses a number of non-standard and non-health-protective procedures in the calculation of the risk estimate for lymphoid cancer from that model, and uses an erroneous “reality check” to support the use of that model. The EOTF assessment improperly chooses the same model and obtains the same risk estimate as TCEQ.

The rationales for EPA’s model selection for the estimation of the lymphoid cancer risks include a number of considerations, not just p-values and AICs (Akaike information criterion), and are discussed in detail in Section 4.1.1.2 of EPA’s 2016 assessment.⁴² EPA’s use of a two-piece spline model, including the approach used for determining the knot, was endorsed by the SAB.⁴³

(ADAF-unadjusted) for lymphoid cancer mortality. Using the Cox regression model favored, regardless of fit, by TCEQ, EPA obtained a unit risk estimate for breast cancer incidence of 1.4×10^{-4} per ppb, which is still almost 2 orders of magnitude greater than TCEQ’s lymphoid cancer risk estimate.

³⁵ Steenland, K; Whelan, E; Deddens, J; Stayner, L; Ward, E. (2003). Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). *Cancer Causes Control* 14: 531-539. <http://dx.doi.org/10.1023/A:1024891529592>

³⁶ Steenland, 2004. Mortality Analyses in a Cohort of 18,235 Ethylene Oxide Exposed Workers: Follow up Extended from 1987 to 1998, K. Steenland, L. Stayner and J. Deddens, *Occupational and Environmental Medicine*, Jan., 2004, Vol. 61, No. 1 (Jan.,2004), pp. 2-7

³⁷ OPP (2020). Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review. (Memorandum) From: Leighton, T; Donovan, W. To: Bailey, J; Bartow, S. November 3, 2020, Pg. 30

³⁸ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris. Pg. 4-40

³⁹ OPP (2020). Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review. (Memorandum) From: Leighton, T; Donovan, W. To: Bailey, J; Bartow, S. November 3, 2020, Pg. 30

⁴⁰ Steenland, 2004. Mortality Analyses in a Cohort of 18,235 Ethylene Oxide Exposed Workers: Follow up Extended from 1987 to 1998, K. Steenland, L. Stayner and J. Deddens, *Occupational and Environmental Medicine*, Jan., 2004, Vol. 61, No. 1 (Jan.,2004), pp. 2-7

⁴¹ Steenland, K; Whelan, E; Deddens, J; Stayner, L; Ward, E. (2003). Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). *Cancer Causes Control* 14: 531-539. <http://dx.doi.org/10.1023/A:1024891529592>

⁴² EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris. e.g., Pg 4-15

⁴³ SAB (Science Advisory Board). (2015). Science Advisory Board Review of the EPAs evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board. [https://yosemite.epa.gov/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/\\$File/EPA-SAB-15-012+unsigned.pdf](https://yosemite.epa.gov/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/$File/EPA-SAB-15-012+unsigned.pdf). Pgs. 1, 13

The model used by TCEQ, on the other hand, is not a legitimate model for the lymphoid cancer data, for reasons discussed in detail in our previous comments to TCEQ (Appendix A), and it results in an extreme underestimation of a reasonable upper bound lymphoid cancer risk estimate. The model used by TCEQ does not provide a good representation of the data, in terms of either global or local fit. Fit statistics showing lack of fit are not presented; instead, TCEQ's use of the model, and rejection of EPA's model, is supported by a flawed "reality check" calculation, which is based on a scientifically inappropriate comparison (see Appendix A comment #13). EPA had considered and rejected the model used by TCEQ.⁴⁴

Not only did TCEQ use an inappropriate model for the data, but also, the reasons given by TCEQ for rejecting EPA's model and risk estimates are fallacious. For example, in addition to the erroneous "reality check" calculations, TCEQ mischaracterized the shape of EPA's extrapolation curve as supralinear, when it is linear, presented misleading discussions about endogenous exposure, and inappropriately applied EPA's unit risk estimate to endogenous exposures, when it is explicitly an estimate of extra risk above background risk, the latter of which includes risk from endogenous exposures.

Several of TCEQ's peer reviewers also recognized that TCEQ's rationales for its model selection and rejection of EPA's model were problematic;⁴⁵ and this was from a more limited group of reviewers, as reviewers #1 and #3 largely declined to comment on these issues on the grounds of the issues being outside these reviewers' area of expertise. For example, in considering the shape of the exposure-response curve at environmental concentrations, reviewer #4 found the arguments on endogenous formation "not particularly convincing"⁴⁶. Reviewer #5 similarly found that "the case against the USEPA URF based on consideration of endogenous levels is not convincing".⁴⁷ Reviewer #6 also took issue with TCEQ's claims about endogenous ethylene oxide.⁴⁸ In addition, both Reviewers #5 and #6 found that TCEQ misconstrued EPA's model by characterizing it as if it were low-dose supra-linear.⁴⁹ Reviewer #6 commented that this assumption "is the TCEQ's chief reason for rejecting the EPA assessment. However, this reflects a misunderstanding and is a mistake"⁵⁰ and further that "TCEQ apparently took the statements in the literature that a supra-linear model is biologically implausible ... and

⁴⁴ EPA (2016). Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide, (CASRN 75-21-8), In Support of Summary Information on the Integrated Risk Information System (IRIS). December 2016. National Center for Environmental Assessment, Office of Research and Development, USEPA, Washington, DC. EPA/635/R-16/350Fa. www.epa.gov/iris. Pg. 4-10

⁴⁵ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020

⁴⁶ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pg 18.

⁴⁷ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pg 46

⁴⁸ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pg 36-37 and 46-47

⁴⁹ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pgs 18,19, and 22.

⁵⁰ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pg 35

inappropriately applied them to the EPA's dose response".⁵¹ Reviewer #5 summarized that "In a nutshell, TCEQ has misconstrued and misrepresented the whole notion of supralinearity.... The DSD is not convincing with respect to its objections to the modeling done by USEPA."⁵²

As summarized in the OPP draft, the EOTF submission suffers from the same pitfalls as the TCEQ assessment and improperly chooses the same model and obtains the same risk estimate as TCEQ.⁵³

3. The Office of Pollution Prevention should not consider the EOTF submission and supporting Exponent report, as they are industry products with no public review, and they are not available to the public.

The EtO Task Force (EOTF) submission and supporting Exponent report are industry products. Exponent is an American engineering and scientific consulting firm that represents Dow Chemical and the American Chemistry Council. Actions by the tobacco and pharmaceutical industries over decades demonstrate that when industry sponsors research, the results are more favorable to the sponsoring industry,^{54,55} and similar patterns are seen in the research funded by the chemical industry.⁵⁶ Industry sponsorship can bias research through various mechanisms, including how they design and conduct a study, selectively report the results, code events, analyze the study data, spinning conclusions, as well as through framing the questions that are asked.^{57,58,59,60} The National Academies of Science, Engineering and Medicine (NASEM) in its review of the EPA IRIS program's systematic review method found that "Funding sources should be considered in the risk-of-bias assessment conducted for systematic reviews that are part of an IRIS assessment."⁶¹ Therefore, as EPA assessments depend on an evidence base that should be as free as possible of bias, EPA must recognize the risk of bias these industry assessments have and should not compare them equally or use them in characterizing and

⁵¹ TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pg 36

⁵² TCEQ (2020b) Final Report for Letter Peer Review of Ethylene Oxide Carcinogenic Dose-Response Assessment Development Support Document. Prepared by Risk Science Center, University of Cincinnati. April 30, 2020. Pg 35.

⁵³ OPP (2020). Ethylene Oxide (EtO). Draft Human Health and Ecological Risk Assessment in Support of Registration Review. (Memorandum) From: Leighton, T; Donovan, W. To: Bailey, J; Bartow, S. November 3, 2020.

⁵⁴ Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. *Cochrane Database Syst Rev*. 2017;(2):MR000033. doi: 10.1002/14651858.MR000033.pub3.; PMID: 28207928.

⁵⁵ White J, Bero LA. Corporate manipulation of research: Strategies are similar across five industries. *Stanford Law & Policy Review*. 2010;21(1):105-34.

⁵⁶ Bero, L., A. Anglemyer, H. Vesterinen and D. Krauth (2016). "The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis." *Environment international* **92-93**: 597-604.

⁵⁷ Odierna DH, Forsyth SR, White J, et al. The cycle of bias in health research: a framework and toolbox for critical appraisal training. *Account Res*. 2013;20(2):127-41

⁵⁸ Fabbri A, Lai A, Grundy Q, et al. The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review. *Am J Public Health*. 2018;108(11):e9-e16.

⁵⁹ Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. *JAMA*. 2010;304(7):793-4.

⁶⁰ Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. *JAMA*. 2008;299(15):1813-7

⁶¹ National Research Council. Review of EPA's Integrated Risk Information System (IRIS) Process. Page. 79. Washington, DC: National Academies Press; 2014.

determining the risks of EtO to human health. Moreover, use of these industry reports is especially questionable when they are not available for public review.

4. The TCEQ/EOTF unit risk estimate should not be considered a legitimate estimate and should not be included in any range of reasonable, scientifically supported estimates.

As discussed above, and in more detail in Appendix A, the model used by TCEQ and EOTF does not adequately represent the lymphoid cancer data, and TCEQ and EOTF discount breast cancer risk. Thus, the TCEQ/EOTF unit risk estimate should not be considered a legitimate estimate and should not be included in any range of reasonable, scientifically supported estimates.

If OPP wants to consider the model uncertainty in the human-based estimates, the range suggested by EPA's 2019 memo would be 6.6×10^{-4} per $\mu\text{g}/\text{m}^3$ to 3.0×10^{-3} per $\mu\text{g}/\text{m}^3$ (not ADAF-adjusted),⁶² although there is much less model uncertainty in the breast cancer estimate, and a more suitable range based solely on the alternate lymphoid cancer models would be 1.1×10^{-3} per $\mu\text{g}/\text{m}^3$ to 3.0×10^{-3} per $\mu\text{g}/\text{m}^3$ (not ADAF-adjusted).

To protect public health, OPP mitigation proposals should recognize potential cancer risk in that range. The EOTF mitigation proposals are necessarily suspect, and may be grossly inadequate, given that the EOTF assessment substantially underestimates the potential risks.

⁶² EPA (2019). IRIS EtO Assessment – Modeling Comparisons and Assessment of Uncertainty. Cover Memorandum from Kristina A. Thayer, Director, Chemical & Pollutant Assessment Division (CPAD), ORD Center for Public Health and Environmental Assessment (CPHEA) to Peter Tsirigotis, Director, Office of Air Quality Planning and Standards (OAQPS), Office of Air & Radiation (OAR); dated October 18, 2019. Memorandum (under the cover Memorandum) from Paul White (CPAD/CPHEA) to Kristina A. Thayer (CPAD/CPHEA). Sensitivity of ethylene oxide risk estimates to dose-response model selection; dated October 18, 2019.

**Appendix A: Comments on Texas Commission on Environmental Quality (TCEQ)
proposed Development Support Document (DSD),“Ethylene Oxide Carcinogenic Dose-
Response Assessment” (28 June 2019)**

September 26, 2019

Comments on Texas Commission on Environmental Quality (TCEQ) proposed Development Support Document (DSD), “Ethylene Oxide Carcinogenic Dose-Response Assessment” (28 June 2019)

Submitted by email to tox@tceq.texas.gov

These comments are submitted on behalf of the undersigned scientists. We declare collectively that we have no direct or indirect financial or fiduciary interest in any chemical or product that is the subject of these comments. The co-signers’ institutional affiliations are included for identification purposes only and do not imply institutional endorsement or support unless indicated otherwise.

We appreciate the opportunity to provide written comments on TCEQ’s Development Support Document (DSD) for ethylene oxide.¹ Ethylene oxide is classified as “carcinogenic to humans” by the International Agency for Research on Cancer² and the US Environmental Protection Agency (EPA),³ and “known to be a human carcinogen” by the National Toxicology Program.⁴ Ethylene oxide has a mutagenic mode of action (MOA) and there is no ‘safe’ level of exposure to this chemical.

In 2016, after public comments, peer review and extensive input from its independent Science Advisory Board (SAB), EPA’s Integrated Risk Information System (IRIS) program finalized a unit risk estimate of 5.0×10^{-3} (per $\mu\text{g}/\text{m}^3$) for ethylene oxide based on lymphoid and breast cancers which also accounted for increased risks from early life exposures (see Table).⁵ The EPA value was derived following a robust scientific review, and using established methodology and current principles for risk assessment as encompassed in EPA’s Guidelines for Carcinogen Risk Assessment and other Agency guidance documents. As such, the EPA value reflects the best available science necessary to ensure the protection of the public’s health from cancer risks. We recommend that TCEQ adopt the EPA value for ethylene oxide.

Our analysis found that TCEQ’s DSD has such serious scientific problems that the conclusions should not be used. As a consequence of these critical problems, TCEQ greatly underestimates the cancer risks posed by ethylene oxide and its cancer unit risk estimates are orders of magnitude below those of EPA, and therefore less health protective (see Table). Of particular note is the completely inadequate treatment of vulnerable populations including women and children, as the DSD ignores risks from breast cancer and fails to account for increased lifetime cancer risks caused by early-life exposures. We are concerned that the DSD unit risk estimate is about 3500 times less protective than the EPA value, does

¹ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Available:

<https://www.tceq.texas.gov/assets/public/implementation/tox/dsd/proposed/jun19/eo.pdf>

² IARC. (2018) Ethylene Oxide. Available: <https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100F-28.pdf>

³ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F. Available: https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=329730

⁴ NTP/NIEHS. (2016) Report on Carcinogens, Fourteenth Edition: Ethylene Oxide. Available: <https://ntp.niehs.nih.gov/ntp/roc/content/profiles/ethyleneoxide.pdf>

⁵ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F. Available: https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=329730

not accurately reflect the science on ethylene oxide cancer risks, and would leave the public, especially women, at unacceptable risk of developing and dying from cancers caused by ethylene oxide.

Table. Comparison of TCEQ and EPA unit risk estimates for ethylene oxide. TCEQ’s estimates for total cancer are orders of magnitude below EPA’s.

	Cancer unit risk estimate (per ug/ m³), including age-dependent adjustment factors	Source
Highest	5.0 x 10 ⁻³	EPA IRIS (2016) ⁶ Total cancer
~3500x difference	4.3 x 10 ⁻³	EPA IRIS (2016) ⁷ Lymphoid cancers
	7.6 x 10 ⁻⁵	TCEQ (2017) ⁸ Total cancer
Lowest	1.4 x 10 ⁻⁶	TCEQ (2019) ⁹ Total cancer (includes lymphoid only)

TCEQ’s conclusions on ethylene oxide cancer risks are not scientifically supported because:

1. **The DSD’s final risk estimate does not include breast cancer risks.**
2. **The DSD discounts the role of expert peer review.**
3. **The DSD incorrectly interprets EPA’s statements regarding the plausible sublinearity of dose-response relationships for endogenous doses of ethylene oxide as also applying to exogenous exposures.**
4. **The DSD ignores background rates of cancer and incorrectly assumes that given endogenous EtO production, low exogenous exposures would not produce biologically meaningful internal doses.**
5. **The DSD incorrectly uses EPA’s unit risk estimate which is applicable to exogenous exposures only to estimate the cancer risks of endogenous ethylene oxide levels.**
6. **The DSD makes flawed claims about EPA’s use of a two-piece spline model for lymphoid cancer and misstates the exposure range over which the model is applied for derivation of the unit risk estimate.**
7. **The DSD criticism of how EPA addressed the knot in the two-piece spline models are contrary to SAB recommendations to the EPA.**
8. **The DSD inappropriately uses a Cox proportional hazards (PH) model for the NIOSH cohort, despite its lack of fit to the data.**
9. **The DSD is incorrect in its claim that EPA should have considered environmental exposures to ethylene.**
10. **The DSD ignores issues with the Swaen et al. (2009) analysis that decreased the ability of that analysis to detect associations for lymphoid cancer.**
11. **The DSD’s approach to deriving a quantitative cancer risk estimate for ethylene oxide exposure has a number of scientific problems that lead to underestimating risk.**

⁶ Total cancer based on human data for breast and lymphoid cancers from EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F.

⁷ Lymphoid cancers based on human data from EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F.

⁸ Total cancer, which TCEQ took from EPA IRIS (2016) based on rodent data. See Appendix A.

⁹ Total cancer, only includes lymphoid cancers based on human data from TCEQ (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment.

- 12. The DSD does not appropriately account for the science showing increased cancer risks from early life exposures to carcinogens with a mutagenic mode of action.**
- 13. The DSD uses a scientifically inappropriate comparison explicitly rejected by the SAB to “predict” the numbers of cases in the NIOSH cohort.**

We appreciate the opportunity to provide public input. Please do not hesitate to contact us with any questions regarding these comments.

Sincerely,

Jennifer Jinot
Scientific consultant to University of California, San Francisco

Veena Singla, PhD
Associate Director, Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

Tracey Woodruff, PhD, MPH
Professor and Director, Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

Swati Rayasam, MSc
Science Associate, Program on Reproductive Health and the Environment
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

DETAILED COMMENTS

1. The DSD's final risk estimate does not include breast cancer risks.

EPA's conclusion of a potential breast cancer hazard from exposure to ethylene oxide (EtO) was supported by the SAB.¹⁰ TCEQ seems to acknowledge a potential breast cancer hazard and considers EPA's quantitative risk estimates for breast cancer, but then rejects EPA's estimates and includes no alternative estimates for breast cancer.

The SAB explicitly endorsed EPA's use of a two-piece spline model for modeling the breast cancer incidence data,¹¹ and EPA's unit risk estimates for breast cancer incidence are based on this model. TCEQ's rationales for rejecting EPA's approach are flawed because TCEQ conflates endogenous (background) exposures with low exogenous exposures, assuming that small increases in exposure above background would not be biologically meaningful, despite the fact that breast cancer has relatively high background rates. There is uncertainty about the risks at low levels of exposure, and this is why EPA applies a linear extrapolation from models derived in the observable range of the data. Use of linear low-exposure extrapolation was supported by the established mutagenic mode of action (MOA) and the SAB. These issues are discussed in more detail below (see comments #3, 4, 6, 11e).

Having rejected EPA's human-based breast cancer risk estimates in the proposed DSD, TCEQ could have considered the rodent-based estimates presented by EPA, rather than completely discounting breast cancer risk. Indeed, in March 2017 TCEQ did exactly that, adopting a value of 7.6×10^{-5} per $\mu\text{g}/\text{m}^3$, the EPA IRIS value for total cancer risk based on rodent data (see Table and Appendix A). Yet, TCEQ's 2019 total risk estimates are for lymphoid cancers only, and the DSD does not provide a valid scientific rationale for not including breast cancer risks in the final unit risk estimate. Because the DSD fails to include breast cancer, TCEQ's final risk estimate is a major underestimation of the actual cancer risks posed by ethylene oxide.

2. The DSD discounts the role of expert peer review.

EPA's EtO carcinogenicity assessment was the subject of extensive review. In addition to review by other offices in EPA and other agencies in the federal government, the assessment twice underwent external peer review by EPA's independent SAB, which included discussions at open public meetings in 2006 and 2014; the SAB also considered public comments made at the meetings. In addition to addressing the SAB's comments, EPA considered public comments made at the 2006 and 2014 SAB meetings as well as at a public meeting in 2013. For the 2014 review by the SAB, the Board set up a

¹⁰ SAB (Science Advisory Board). (2015) Science Advisory Board Review of the EPA's evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Available: [https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/\\$File/EPA-SAB-15-012+unsigned.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/$File/EPA-SAB-15-012+unsigned.pdf)

¹¹ Id. Pp. 1, 12

panel of 14 experts from a range of relevant disciplines. After the review, the panel's report was reviewed and endorsed by the larger SAB.

As described in the comments below, the SAB explicitly endorsed EPA's approaches and rejected the model ultimately chosen by TCEQ, where the Commission's conclusions and approaches differed from those of EPA (e.g., discounting the breast cancer models, rejecting two-piece spline models, not using linear low-exposure extrapolation). The DSD does not present new data or evidence that was not considered by the SAB, nor does it provide an appropriate scientific explanation for the significant departures from EPA's methodology. In contrast to the Agency, academic and public expert input and extensive peer review of the EPA assessment, the DSD has not been peer reviewed or subject to any external comments.

3. The DSD incorrectly interprets EPA's statements regarding the plausible sublinearity of dose-response relationships for endogenous doses of EtO as also applying to exogenous exposures.

The DSD states EPA determined "that the low-dose region of the EtO dose-response curve is highly plausibly sublinear..."¹² but this interpretation of the EPA assessment is incorrect. EPA made no such determination about low-dose exogenous exposures.

Rather, EPA made general statements¹³ in the context of conceptual models presented by Starr and Swenberg¹⁴ and Crump et al.¹⁵ In this context, EPA was referring to a range of hypothetical *endogenous* doses from no (zero) endogenous exposure to the point of no (zero) exogenous exposure. The rationale for postulating that the dose-response relationships for relevant cancers across that hypothetical range of doses are likely to be sublinear is based on the conceptual model presented in detail by Crump et al. (2014). In brief, the reasoning is that the body has defense mechanisms (e.g., DNA repair mechanisms) to deal with endogenous exposures. However, these defenses are imperfect and limited, which may account for some level of background cancer risk even without exogenous exposures; and as endogenous doses increase across this hypothetical range, the body's available defenses get diminished, such that the slope of the dose-response curve may be essentially linear at the point of zero exogenous exposure (see Figure 1 in Crump et al. (2014)). The postulated sublinearity is not meant to apply to the range of exogenous exposures.

EPA's unit risk estimates are explicitly for extra risk *above background*, i.e., *above* the risk from endogenous doses (unit risk estimates are derived from exposure-response modeling of exogenous exposures; endogenous doses are common to both exposed and unexposed subjects, independent of

¹² TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 1

¹³ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F. pg. 4-95.

¹⁴ Starr TB, Swenberg JA. (2013) A novel bottom-up approach to bounding low-dose human cancer risks from chemical exposures. Regul. Toxicol. Pharmacol. 65 (3), 311–315.

¹⁵ Crump KS, Bussard DA, Chen C, Jinot J, Subramaniam R. (2014) The "bottom-up" approach does not necessarily bound low-dose risk Regul Toxicol Pharmacol 70:735-736.

exogenous exposure, and thus are part of background risk). Variability in levels of background doses of endogenous EtO are accounted for in the modeling of the exogenous exposures, along with other sources of variability. While sublinearity across endogenous doses is plausible, one cannot infer anything from that about the exposure-response relationship at low exogenous exposures. Thus, the DSD's application of the hypothetical sublinear dose-response relationship for endogenous exposures to exogenous exposures, especially in light of background cancer rates (see comment #4), is not scientifically supported.

4. The DSD ignores background rates of cancer and incorrectly suggests that given endogenous EtO production, low exogenous exposures would not produce biologically meaningful internal doses.

The DSD states that “ambient EtO concentrations significantly less than 1 ppb...would not be expected to produce biologically meaningful internal doses considering the range of normal endogenously-produced background EtO levels.”¹⁶ However, normal endogenous EtO exposures may contribute to background cancer risks for lymphoid cancers and for breast cancers in females, as these are relatively common cancer types in the general population. As cited on p. 4-95 of EPA's assessment,¹⁷ lymphoid cancers have a background lifetime incidence risk on the order of 3%, while the background lifetime incidence risk for breast cancer in females is on the order of 15%.

Low exogenous EtO exposures would be additive to the endogenous exposure and to background cancer processes, consistent with general principles of quantitative risk assessment.^{18, 19} As to the variability in background doses of endogenous EtO, this is accounted for in the modeling of the exogenous exposures, as discussed in comment #3 above. Thus, DSD ignoring low levels of exogenous exposure claiming they are not biologically meaningful is not scientifically justified and results in an underestimation of risk. For example, the DSD ignores levels of exogenous exposure that EPA determined to be associated with upper bound extra risks of 10^{-4} (0.01%).

¹⁶ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 1

¹⁷ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F. pg. 4-95.

¹⁸ Crump KS, Hoel DG, Langley H, Peto R. (1976) Fundamental carcinogenic processes and their implications for low dose risk assessment. *Cancer Res.* 36:2973–2979.

¹⁹ Lutz WK, Gaylor DW, Conolly RB, Lutz RW. (2005) Nonlinearity and thresholds in dose-response relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small differences in individual susceptibility. *Toxicol Appl Pharmacol* 207:S565-S569.

5. The DSD incorrectly attempts to estimate the cancer risks of endogenous EtO levels using EPA's unit risk estimate which is applicable to exogenous exposures only.

The DSD applies EPA's unit risk estimate to endogenous ethylene oxide exposures,²⁰ but as noted above (comments #3, 4), EPA's unit risk estimates are for exogenous exposures only (extra risk *above background*²¹) and cannot be used to infer anything about risks from endogenous exposure. The extent of cancer risks from endogenous levels of EtO is not something that can be estimated from current knowledge.

6. The DSD makes flawed claims about EPA's use of a two-piece spline model for lymphoid cancer and misstates the exposure range over which the model is applied for derivation of the unit risk estimate.

The DSD claims that the EPA model over-predicts the NIOSH cohort results.²² However, TCEQ's approach to predicting cases is flawed (see comment #13 below for a discussion of problems in the TCEQ's approach). In fact, EPA's model provides a reasonably good representation of the NIOSH data, as demonstrated by the statistical and visual fits. As seen in Figure 4-3 of EPA's assessment,²³ the model actually underestimates the categorical relative risks (RRs) determined nonparametrically (i.e., without any assumptions about the exposure-response relationship across the exposure categories) for the exposure quartiles.

The DSD claims that EPA was wrong to use a supralinear model.²⁴ However, the underlying data exhibit a supralinear exposure-response relationship. This is demonstrated by the shape of the nonparametric categorical results, as well as by the fact that the best-fitting models are supralinear (e.g., the Cox regression model with log cumulative exposure; see Table 4-6 of EPA assessment²⁵).

²⁰ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 24-25

²¹ Technically, when estimating extra risk (above background) from exposure-response models of occupational cohorts, background risk can also include risk from background levels of ambient (exogenous) exposure. Generally, this contribution is negligible and can be ignored when applying unit risk estimates to calculate risks from environmental exposure levels. Moreover, as discussed above with respect to endogenous exposures, just because the risk from background levels of ambient exposure is included in the background in the extra risk calculations does not mean that background levels of ambient exposure are without risk. Given uncertainties regarding the risk from background levels of ambient exposure, it is public-health-protective to apply the unit risk estimate to all exogenous exposures, i.e., down to zero exogenous exposure, and it is a minimal additional extrapolation relative to the extrapolation from higher occupational exposures to background levels of exogenous exposure used in the derivation of the unit risk estimates.

²² TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 2; Appendix 3

²³ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F.

²⁴ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 3

²⁵ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F.

Furthermore, EPA's independent SAB endorsed the use of two-piece spline models for such data,²⁶ recognizing the utility of such models for reflecting local behavior in the data more readily than the single-parameter models. In fact, EPA used a two-piece linear spline model to account for high-exposure plateauing while specifically avoiding the excessive supralinear curvature in the lower-exposure range objected to by TCEQ and sources it cites regarding supralinear models.²⁷

A mechanistic explanation for overall supralinear exposure-response relationships in the observable range of the EtO epidemiological data may not be known; however, such relationships are not uncommon with epidemiological data and there are other possible explanations.²⁸ Moreover, after modeling all of the data using the two-piece spline model, EPA estimated a point of departure (POD) at the low end of the observable range and used linear low-exposure extrapolation from the POD to derive the unit risk estimate, consistent with EPA's guidelines.²⁹ (See comment #11e below for more discussion of EPA's approach to deriving unit risk estimates.) The conclusion of a mutagenic MOA, which was a finding of both EPA and the TCEQ, provides support for linear *low-exposure extrapolation*. Contrary to intimations by TCEQ, the mutagenic MOA does not preclude high-exposure plateauing, such as exemplified by tumors in rats exposed to vinyl chloride.³⁰

Similarly, the plausibility of sublinearity in the conceptual range of endogenous exposures from internal doses of zero up to the point of zero exogenous exposure does not rule out the models used by EPA for exogenous exposures, i.e., supralinearity in the observable range from higher exposures and linear extrapolation for lower exposures.

Thus, the DSD's rationales for rejecting the model used by EPA are not valid.

7. The DSD criticism of how EPA addressed the knot in the two-piece spline models are contrary to SAB recommendations to the EPA.

The DSD objected to the fact that EPA did not include the knot as a parameter in its estimations of the Akaike Information Criterion (AIC).³¹ Inclusion of the knot as a parameter would have been one way to do the calculation; however, the SAB supported EPA's approach. Consistent with SAB recommendations, the EPA did not make its model selections based solely on the AICs. As

²⁶ SAB. (2015) Science Advisory Board Review of the EPA's evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012) Pg. 12. Available: [https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/\\$File/EPA-SAB-15-012+unsigned.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/BD2B2DB4F84146A585257E9A0070E655/$File/EPA-SAB-15-012+unsigned.pdf)

²⁷ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 19-20

²⁸ Stayner L, Steenland K, Dosemeci M, Hertz-Picciotto I. (2003) Attenuation of exposure-response curves in occupational cohort studies at high exposure levels. *Scand J Work Environ Health* 2003;29(4):317-324.

²⁹ EPA. (2005) Guidelines for carcinogen risk assessment [EPA Report] (pp. 1-166). (EPA/630/P-03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. Available: <http://www2.epa.gov/osa/guidelines-carcinogen-risk-assessment>

³⁰ EPA. (2000) Toxicological review of vinyl chloride [EPA Report]. (EPA/635/R-00/004). Washington, DC: U.S. Environmental Protection Agency.

³¹ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 48-50, Appendix 5

recommended by the SAB, EPA also gave consideration to the ability of models to reflect local behavior, e.g., prioritizing two-piece spline models, and to parsimony.³² The SAB singles out the knot as a parameter that could be fixed in the interest of parsimony, stating “To elaborate further, in some settings the principle of parsimony may suggest that the most informative analysis will rely upon fixing some parameters rather than estimating them from the data.... In the draft assessment, fixing the knot when estimating linear spline model fits from relative risk regressions is one such example.” Moreover, the SAB fully understood how EPA determined the knot, having reviewed the Agency’s approach as a charge question, finding it “scientifically appropriate and a practical solution that is transparently described.”³³ Thus, the DSD objections that the knot was estimated before it was fixed are not persuasive.

8. The DSD inappropriately uses a Cox proportional hazards (PH) model for the NIOSH cohort, despite its lack of fit to the data.

As a central part of its analysis to calculate the cancer unit risk estimate, the DSD uses a model for the NIOSH cohort that they note does not provide a statistically significant fit to the data (though the DSD does not present a *p*-value). In addition, the approach that they used to demonstrate that their model provides good “predictions” of the number of cases in the NIOSH cohort is flawed (see comment #13 below).

Furthermore, the model used by TCEQ is inherently sublinear and cannot reflect the overall supralinear shape of the exposure-response relationship (See model “ $e^{(\beta \cdot \text{exp})}$ ” in Fig 4-3 of EPA’s assessment and the *p*-values in Table 4-6).³⁴ The Cox PH model for lymphoid cancers in males and females in the NIOSH cohort has a *p*-value 0.22, while the best-fitting supralinear model has a *p*-value of 0.02—a much lower and statistically significant value, indicating the supralinear model provides a better fit to the data. The Cox PH model was presented in EPA’s assessment for comparison with other models, therefore the SAB was able to consider it as an option, and yet, the SAB did not promote it but instead endorsed two-piece spline models.

EPA and the SAB recognized the importance of local fit to the data, as well as overall fit. The two-piece spline model used by EPA, and endorsed by the SAB, can represent the increasing response at lower exposures (without excessive curvature at the lowest exposures) and the relative plateauing at higher exposures, as discussed above (comment #6). To estimate the risks of environmental exposure levels from higher exposure data, such as occupational data, capturing this local behavior at the lower exposure range of the data is especially important because it reflects the data range most relevant to the even lower exposures of interest.

³² SAB. (2015) Science Advisory Board Review of the EPA’s evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012) Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board. Pg. 12

³³ Id. pg. 13

³⁴ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F.

In contrast, the Cox PH model used by TCEQ cannot accommodate supralinear exposure-response data and, in particular, cannot reflect the exposure-response relationship in the lower exposure range of the data. Instead, in order to attempt to fit the high-exposure plateauing, such a model must inflate the internal baseline hazard rate and depress the low-exposure slope. This is illustrated in Figure 21 of the DSD, where the dotted blue line depicts the model used by TCEQ with an approximated baseline hazard rate shown relative to the nonparametric baseline hazard rate. It is apparent from this depiction that the baseline rate in the Cox PH model has been markedly overestimated relative to the nonparametric (categorical) baseline (RR = 1). The nonparametric baseline, however, is the best available estimate of the baseline hazard rate in the cohort because it is based on the 0 (lagged) cumulative exposure group without any assumptions about the shape of the exposure-response model for the exposed workers and, thus, without any influence of the higher-exposure data on the model fit to the lower-exposure data.

Despite these clear problems, TCEQ goes on to calculate the point of departure (POD) using the sublinear Cox PH model, and Table 30 on p. 93 of the DSD presents a confidence score of “high” for the POD. This score is totally unwarranted because the Cox PH model does not provide a statistically significant fit to the data and is inconsistent with the overall shape of the exposure-response data. Moreover, the “predictive” value of the model is based on a flawed approach, as discussed in comment #13 below. Finally, even if the model and predictions were valid, there are insufficient data in the range of the POD, which was calculated at a risk level of 1 in 100,000, to conclude that the model yields reliable estimates in that range, as discussed in comment #11.

For all of these reasons, the DSD’s model selection and POD derivation, and the subsequent cancer unit risk estimates based on them, are not scientifically supported.

9. The DSD is incorrect in its claim that EPA should have considered environmental exposures to ethylene.

Environmental exposures to ethylene would be part of background risk and would not affect EPA’s EtO unit risk estimate, which is for extra risk *above background*.

10. The DSD ignores issues with the Swaen et al. (2009) analysis that decreased the ability of that analysis to detect associations for lymphoid cancer.

The DSD cites the Swaen, et al. (2009)³⁵ study of the Union Carbide Corporation (UCC) as reporting that “no indications were found for excess cancer risks from EtO exposures, including lymphohematopoietic malignancies,”³⁶ however the Swaen analysis has important limitations:

- a) The trend analyses were done using the sublinear Cox model, which would be limited in detecting supralinear trends (see comment #8).

³⁵ Swaen, GMH; Burns, C; Teta, JM; Bodner, K; Keenan, D; Bodnar, CM. (2009) Mortality study update of ethylene oxide workers in chemical manufacturing: A 15 year update. J Occup Environ Med 51: 714-723.

³⁶ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 14

- b) The categorical analyses were based on standardized mortality ratios (SMRs), which are notoriously deficient for analyzing occupational epidemiology data because workers often have background disease mortality rates below those of the general population. This concept is called the “healthy worker effect” (HWE), although it can reflect differences between an occupational cohort and the general population beyond health. In fact, EPA’s SAB specifically recommended that epidemiological results based on external standards, e.g., SMRs, be down-weighted, stating “[t]he presence of the healthy worker effect cannot be denied in these occupational data and the use of an external standard for comparison does not avoid healthy worker types of biases.”³⁷
- c) The long follow-up in the UCC cohort, well past the occurrence of non-negligible exposures,³⁸ was likely observing proportionately more background cases associated with increasing age of the cohort than cases associated with exposures in the distant past. In other words, most of the workers who would die of exposure-related lymphoid cancers would likely have already passed; thus, proportionately more of the new cases picked up in the extended follow-up would be background cases. This excessive follow-up, given the time that had lapsed since non-negligible exposures ceased, would make it more difficult to observe an exposure-related effect. (See also p. A-30 to A-31 of Appendix A of EPA (2016b) for more discussion.³⁹)

The DSD’s interpretation of the Swaen study does not account for these critical limitations.

11. The DSD’s approach to deriving a quantitative cancer risk estimate for ethylene oxide exposure has a number of scientific problems that lead to underestimating risk.

- a) TCEQ’s quantitative risk estimates are for lymphoid cancer only and do not include the risks for breast cancer in females (see also comment #1).
- b) For lymphoid cancer, as discussed above (comment #8), the DSD selected a sublinear Cox PH model that does not fit the data.
- c) In addition, the use of a 70-year cut-off in the lifetable analysis is not consistent with a default (average) lifetime of 70 years. EPA also uses a default average lifetime of 70 years but recognizes that 70 years should not be used as a cut-off in lifetable analyses, because in such analyses, actual demographic data about mortality rates at different ages are incorporated rather than using an average default lifetime. Truncating the analysis at 70 years actually corresponds to an average lifetime of less than 70 years because the hypothetical population tracked in the lifetable analysis is allowed to die at younger ages than the would-be average of 70 years but not allowed to live beyond 70 years. In contrast, truncating the lifetable analysis at 85 years corresponds to an average lifetime of about 75 years, which is close to the default average of 70 years.⁴⁰

³⁷ SAB. (2015) Science Advisory Board Review of the EPA’s evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Pg. 18-19

³⁸ Exposures in this cohort beyond 1989 were considered negligible by Swaen et al. (2009).

³⁹ EPA. (2016) Evaluation of the inhalation carcinogenicity of ethylene oxide: Appendices [EPA Report]. (EPA/635/R-16/350Fb).

⁴⁰ Id. p. H-35 of Appendix H.

- d) Another difference between the EPA and TCEQ approaches is that the EPA estimates are for cancer incidence, whereas the TCEQ estimates are for mortality. The SAB endorsed EPA's approach for calculating incidence estimates from mortality data.⁴¹
- e) Moreover, in the DSD, the modeling for lymphoid cancer was apparently done all the way down to a risk level of 1 in 100,000 using the (non-fitting) sublinear model. In so doing, the TCEQ over relies on a sublinear model that doesn't describe the overall data well and certainly can't reliably estimate risks at corresponding low levels of exposure where there are few data. In other words, this approach assumes that the sublinear model is valid not only in the observable range of the data, contrary to findings that the underlying exposure-response data are more supralinear in shape, as discussed above (comment #8), but also in the lower exposure range, where the data are insufficient to estimate risks with any confidence. On p. 5 of the DSD, the TCEQ criticizes the EPA, stating "High-dose carcinogenicity data alone are incapable of informing truly low-dose risk"; however, it is the TCEQ, not the EPA, that models from the high-dose data down to a risk level of 1 in 100,000.

In contrast, EPA's approach does not presume to be able to estimate risks at such low levels. Instead, EPA's Guidelines on Carcinogen Risk Assessment advocate modeling the data and then selecting a POD near the low end of the observable range, i.e., the low end of the range in which increased risks might be reasonably detectable above background variability, and applying an extrapolation method from the POD.⁴² In the absence of sufficient evidence that a nonlinear approach is warranted, the default approach is to use linear extrapolation. In the case of EtO, the use of linear extrapolation from the POD is supported by the finding of a mutagenic MOA, in accordance with EPA's guidance.⁴³ Linear extrapolation was also endorsed by the SAB.⁴⁴ Given the background rates of lymphoid cancer, EPA chose a POD of 1% extra risk,⁴⁵ or 1 in 100, which is far from the risk level of 1 in 100,000 used by TCEQ.

TCEQ's own protocol for developing toxicity factors provided in Section A1.1 of Appendix 1 of the DSD states that one "extrapolate[s] from the adjusted POD to lower exposures based on MOA analysis"; however, as discussed above, in this DSD, modeling was done all the way down to a risk level of 1 in 100,000 using a (non-fitting) sublinear model. The DSD's approach is inconsistent with the guidance of EPA and other agencies (including possibly TCEQ as well, according to their protocol), in which a POD is selected near the low end of the observable range and then the mutagenic MOA established for EtO would support linear low-dose extrapolation.

⁴¹ SAB. (2015) Science Advisory Board Review of the EPA's evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012) Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board. Pg. 15.

⁴² EPA. (2005) Guidelines for carcinogen risk assessment [EPA Report] (pp. 1-166). (EPA/630/P-03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.

⁴³ Id.

⁴⁴ SAB. (2015) Science Advisory Board Review of the EPA's evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012) Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board.

⁴⁵ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F. pg. 4-22

See also Section A.2.20 of Appendix A of EPA's assessment (2016b) for more discussion of the above issues related to the lymphoid cancer risk estimates.⁴⁶ The section critiques the approach used by Valdez-Flores et al. (2010), which was largely adopted in this DSD.

All of these scientific flaws contribute to the DSD's final unit risk estimate being a gross underestimate of the cancer risks demonstrated by the evidence.

12. The DSD does not appropriately account for the science showing increased cancer risks from early life exposures to carcinogens with a mutagenic mode of action.

The DSD states that the approach of Sielken and Valdez-Flores (2009) was used to apply the age-dependent adjustment factors (ADAFs) to the cancer risk estimates;⁴⁷ however, the ADAF calculations were not done correctly by Sielken and Valdez-Flores (2009). Early life exposures to chemicals with a mutagenic MOA such as EtO can increase lifetime cancer risk, and thus EPA guidance recommends the application of ADAFs in quantitative risk calculations to adjust for this potential increased susceptibility.⁴⁸ This means that exposure to a mutagenic carcinogen at a young age can increase a person's risk of developing cancer later in life. Thus, the ADAFs are designed to adjust *lifetime risk*, to reflect increased lifetime cancer risk from increased susceptibility to early-life exposures.⁴⁹ But Sielken and Valdez-Flores (2009) incorrectly multiply the ADAFs to the age-specific cancer mortality rates in the lifetable, which just applies the factors to risk for those younger age groups and ignores increased risks for older ages (discussed in more detail in EPA's assessment⁵⁰). In addition, assuming increased early-life susceptibility and applying the ADAFs along with the Cox PH model in the lifetable analysis, as done by Sielken and Valdez-Flores (2009), is inconsistent with a major assumption of the Cox model, that RR is independent of age.

In fact, because of the lagged exposures and low cancer mortality rates at young ages, applying the ADAFs just to young age groups had a negligible effect on the final risk estimates in Sielken and Valdez-Flores (2009). In contrast, the approach that correctly accounts for the science showing that early life exposures increase lifetime cancer risks (used by EPA) increased the lifetime risk estimates by about 22% (for both female breast cancer and lymphoid cancer combined).⁵¹

⁴⁶ EPA. (2016) Evaluation of the inhalation carcinogenicity of ethylene oxide: Appendices [EPA Report]. (EPA/635/R-16/350Fb).

⁴⁷ TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Pg. 61

⁴⁸ EPA. (2005b) Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens (pp. 1-125). (EPA/630/R-03/003F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. https://www3.epa.gov/airtoxics/childrens_supplement_final.pdf

⁴⁹ Id.

⁵⁰ EPA. (2016) Evaluation of the inhalation carcinogenicity of ethylene oxide: Appendices [EPA Report]. (EPA/635/R-16/350Fb). p. A-34 to A-35 of Appendix A

⁵¹ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F. Section 4.4.

The DSD's confidence score for sensitive populations was "medium." However this score is not warranted because TCEQ discounts the breast cancer risk in females and misapplies the ADAFs for susceptibility from early-life exposures, both of which result in underestimations of the risks posed by ethylene oxide.

13. The DSD uses a scientifically inappropriate comparison explicitly rejected by the SAB to "predict" the numbers of cases in the NIOSH cohort.


TCEQ's method for predicting the number of cases in the NIOSH cohort relies on a standardized mortality ratio (SMR) comparison.⁵² As discussed in comment #10b, SMRs are notoriously deficient for analyzing occupational epidemiology data because workers often have background disease mortality rates below those of the general population. This concept is called the "healthy worker effect" (HWE), although it can reflect differences between an occupational cohort and the general population beyond health. In fact, EPA's SAB specifically recommended that epidemiological results based on external standards, e.g., SMRs, be down-weighted.⁵³ The SAB states "The presence of the healthy worker effect cannot be denied in these occupational data and the use of an external standard for comparison does not avoid healthy worker types of biases."

In the DSD, basing the "predictions" on an SMR comparison ignores the healthy worker effect apparent in the data and inflates the background risk expected in the cohort, equating it to the background risk in the general population. Therefore, all the relative risk (RR) models, which are based on an internal analysis estimating increases in risk relative to the actual (lower) background rates in the cohort, will overestimate cohort case numbers when the increases in risk are forced to be relative to the higher background rates of the general population. This will be true unless they're underestimating the risks to begin with, like the sublinear model selected by the TCEQ. The selected EPA models naturally "overpredict" case numbers under this flawed approach.

Instead, if one performs a more appropriate comparison based on the results of internal analyses (within the cohort), one can see that the sublinear model used by TCEQ is a poor predictor of the nonparametric categorical RR estimates for the exposure quartiles; see model " $e^{(\beta \cdot \text{exp})}$ " in Fig 4-3 of EPA's assessment.

⁵² TCEQ. (2019) Ethylene Oxide Carcinogenic Dose-Response Assessment. Appendix 3.

⁵³ SAB. (2015) Science Advisory Board Review of the EPA's evaluation of the inhalation carcinogenicity of ethylene oxide: Revised external review draft - August 2014 [EPA Report]. (EPA-SAB-15-012). Pg. 18-19



Reproduction of Figure 4-3 from EPA assessment, with black rectangles and text added to highlight TCEQ's model, the categorical RR estimates, and EPA's selected model.⁵⁴

Comparing TCEQ's model, depicted by the solid blue curve near the bottom of the graph, to the nonparametric categorical RR estimates, depicted by the filled purple circles, shows that the model selected by the TCEQ substantially underestimates the nonparametric categorical RR estimates. In contrast, the EPA model depicted by the dashed red line (linspline1600) is a much better predictor of the nonparametric categorical RR estimates. As noted in comment #8, the nonparametric baseline estimate is the best available estimate of the baseline hazard rate in the cohort because it is based on unexposed referent group without any assumptions about the shape of the exposure-response model for the exposed workers and, thus, without any influence of the higher-exposure data on the model fit to the lower-exposure data. Similarly, the categorical RR estimates for the exposed groups are estimated with no assumptions about the shape of the exposure-response relationship across the groups.

In addition, proper comparisons of models against data should be based on maximum likelihood estimates (MLEs), as done in Figure 4-3 of EPA's assessment, not upper bounds as primarily reported by TCEQ.

Thus the DSD's reliance on this flawed calculation to support its rejection of EPA's model and its own use of a poorly fitting model is not supported by the evidence.

⁵⁴ EPA. (2016) Evaluation Of The Inhalation Carcinogenicity Of Ethylene Oxide (Final Report). EPA/635/R-16/350F.

**Appendix A: TCEQ (March 2017) Ethylene Oxide Dose Response Assessment
Review**

Ethylene Oxide

CAS# 75-21-8

March 6, 2017

The Toxicology Division (TD) of the TCEQ has reviewed the 2016 dose-response assessment for the USEPA IRIS unit risk factor (URF of $3E-03$ per $\mu\text{g}/\text{m}^3$) for ethylene oxide. Due to concerns about the assessment, the TD has adopted an alternative URF of $7.6E-05$ per $\mu\text{g}/\text{m}^3$ (see below).

USEPA (2016) derived a URF for ethylene oxide (EtO) based on a large epidemiologic study conducted by the National Institute for Occupational Safety and Health (NIOSH). Overall, some human epidemiology studies support an association of cancer with inhalation exposure to EtO (although many of the associations are weak), whereas other do not. Animal studies do show a causal association for some of the cancer endpoints observed in the human studies.

The TCEQ has chosen not to adopt the USEPA URF for EtO due to several deficiencies in the USEPA assessment including:

1. The NIOSH key study used to derive the URF is unpublished and unavailable to the public.
2. Conclusions from the individual key studies used by NIOSH (Steenland et al. 2004 and Steenland et al. 2003) to derive the URF support, at best, positive exposure-response trends and weak causal associations between EtO and cancer.
3. There are several modeling issues in the NIOSH study, as discussed in Valdez-Flores and Sielken (2013) and Valdez-Flores et al. (2010), resulting in over-estimation of cancer risks. For example:
 - a. USEPA calculated an excess cancer risk for 85 years, instead of the 70-year default commonly used by the TCEQ and others for cancer risk assessment (e.g., TCEQ 2015).
 - b. Statistical procedures used to generate lower effective concentrations (LECs) are insensitive to the observed data. Furthermore, the observed shape of the dose-response relationship and the maximum likelihood estimate (MLE) of the environmental concentration (EC) is often preferable to an LEC for a risk estimate based on human data (e.g., by definition it is the best model fit, and uncertainty is reduced by the use of human data).

Alternative URFs are available and are presented in the USEPA IRIS assessment for EtO. URFs based on human epidemiology data and discussed in the USEPA IRIS assessment include:

1. Valdez-Flores et al. (2010) calculated several URFs based on multiple cancer endpoints, for both males and females, using two datasets: Steenland et al. (2004) and Union Carbide Corporation (UCC) mortality data of EtO chemical manufacturing workers. However, there was no evidence of a positive cumulative dose-response for any cancer endpoint, and only the highest exposure groups showed a statistically significant increase in cancer. Therefore, we did not adopt any of the URFs from this study.

2. Kirman et al. (2004) calculated a URF based on leukemia mortality data in combined earlier NIOSH and UCC cohorts (Stayner et al. 1993 and Teta et al. 1993, respectively). We chose not to adopt the URF from this study for several reasons: 1) it is based on older epidemiology studies that don't incorporate the most up-to-date information, 2) this study did not evaluate breast cancer, 3) the authors state that "the epidemiology data do not demonstrate a causal relationship between (EtO) exposure and leukemia" and 4) as discussed in detail in USEPA (2016), worker exposure data from the UCC cohort are unreliable for risk assessment purposes.

URFs derived based on studies conducted in both rats and mice are discussed in the USEPA IRIS assessment and include:

1. Kirman et al. (2004) calculated a URF based on four animal studies in mice and rats. URFs calculated from data for mononuclear cell leukemia tumors were not used due to uncertainties associated with relevance of this tumor type to humans. Lymphoma tumor data didn't show a positive dose-response in male or female mice so URFs calculated from these data were not used.
2. USEPA (2016) analysis of female tumor data from NTP (1987) yielded a URF of $7.6E-05$ per $\mu\text{g}/\text{m}^3$. *The TCEQ chose to adopt this URF for EtO based on the high quality of the NTP (1987) study, positive dose-response relationships observed for multiple tumor types in female mice, and concordance with tumor types observed in human epidemiology studies.*

Shannon Ethridge, MS, DABT

Jennifer McKinney, PhD

Toxicology Division

References

- Kirman, CR; Sweeney, LM; Teta, MJ; Sielken, RL; Valdez-Flores, C; Albertini, RJ; Gargas, ML. (2004). Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: Cancer potency estimates for ethylene oxide. Risk Anal 24: 1165-1183. <http://dx.doi.org/10.1111/j.0272-4332.2004.00517.x>
- NTP (National Toxicology Program). (1987). Toxicology and carcinogenesis studies of ethylene oxide (CAS no 75-21-8) in B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser 326: 1-114.
- Stayner, L; Steenland, K; Greife, A; Hornung, R; Hayes, RB; Nowlin, S; Morawetz, J; Ringenburg, V; Elliot, L; Halperin, W. (1993). Exposure-response analysis of cancer mortality in a cohort of workers exposed to ethylene oxide. Am J Epidemiol 138: 787-798.
- Steenland, K; Whelan, E; Deddens, J; Stayner, L; Ward, E. (2003). Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). Cancer Causes Control 14: 531-539. <http://dx.doi.org/10.1023/A:1024891529592>

- Steenland, K; Stayner, L; Deddens, J. (2004). Mortality analyses in a cohort of 18 235 ethylene oxide exposed workers: Follow up extended from 1987 to 1998. *Occup Environ Med* 61: 2-7.
- Teta, MJ; Benson, LO; Vitale, JN. (1993). Mortality study of ethylene oxide workers in chemical manufacturing: A 10 year update. *Br J Ind Med* 50: 704-709.
- U.S. Environmental Protection Agency (USEPA). 2016. Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide [CASRN 75-21-8] In Support of Summary Information on the Integrated Risk Information System (IRIS). (EPA-635/R-16/350Fa). National Center for Environmental Assessment Office of Research and Development: US Environmental Protection Agency Washington, DC.
https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/1025_summary.pdf
- Valdez-Flores, C; Sielken, RL, Jr; Teta, MJ. (2010). Quantitative cancer risk assessment based on NIOSH and UCC epidemiological data for workers exposed to ethylene oxide. *Regul Toxicol Pharmacol* 56: 312-320. <http://dx.doi.org/10.1016/j.yrtph.2009.10.001>